Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 142 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Choline Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

Synergy Between Choline and DHA

NCT03194659
View directory record Official record
Conditions
Pregnancy
Interventions
Choline
Dietary Supplement
Lead sponsor
Cornell University
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Ithaca, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 17, 2026, 7:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dietary Supplementation to Increase Serum Choline Levels

NCT02403804
View directory record Official record
Conditions
Healthy
Interventions
Phosphatidylcholine, Betaine (588 mg qam and 412 mg qpm), Betaine (1000 mg BID)
Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 17, 2026, 7:27 PM EDT
Completed Phase 1 Interventional

Cancer Localization in the Prostate With F-18 Fluorocholine Positron Emission Tomography

NCT01310192
View directory record Official record
Conditions
Prostate Cancer
Interventions
Fluourine-18 Fluoromethylcholine PET/CT Imaging
Device
Lead sponsor
Queen's Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Tripler AMC, Hawaii
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 17, 2026, 7:27 PM EDT
Completed Phase 4 Interventional Results available

Effect of Neuromuscular Blockade on Pulmonary Complications in Elective Cardiac Surgery

NCT02635542
View directory record Official record
Conditions
Neuromuscular Blockade, Postoperative Complications
Interventions
Succinylcholine, Cisatracurium
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 17, 2026, 7:27 PM EDT
Completed Phase 2 Interventional Results available

11C- and 18F-Choline PET/MR Imaging for Prostate Cancer

NCT02397408
View directory record Official record
Conditions
Prostate Cancer
Interventions
Carbon C 11 Choline, Fluorine F 18 Choline, Positron Emission Tomography (PET) / Magnetic Resonance Imaging (MRI)
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Oct 17, 2026, 7:27 PM EDT
Approved For Marketing No phase listed Expanded access

Detecting Recurrent Prostate Cancer With C-11 Choline Positron Emission Tomography: An Expanded Access Study

NCT02355054
View directory record Official record
Conditions
Cancer of the Prostate
Interventions
C-11 Choline PET Imaging
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 17, 2026, 7:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults

NCT05319912
View directory record Official record
Conditions
Healthy
Interventions
ALXN1840 Enteric-coated Tablet, ALXN1840 Non-coated Capsule, Omeprazole
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Oct 17, 2026, 7:27 PM EDT
Not yet recruiting Phase 4 Interventional

REMIfentanil (2 vs. 4 mcg/kg) Facilitated Intubation Without Neuromuscular Blockade Versus Succinylcholine and Rocuronium With Sugammadex for Endotracheal Intubation in Spine Surgery Requiring Motor Evoked Potential Monitoring

NCT07835295
View directory record Official record
Conditions
Airway Management, Endotracheal Intubation
Interventions
Low-Dose Remifentanil, High-Dose Remifentanil, Succinylcholine, Rocuronium, Sugammadex
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 17, 2026, 7:27 PM EDT
Completed Not applicable Interventional Results available

Assessing 11C-Choline (11C-CH) PET to Distinguish True Tumor Progression From Pseudoprogression in High-grade Gliomas

NCT02849171
View directory record Official record
Conditions
Brain Cancer
Interventions
PET scan, C-Choline
Device · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Oct 17, 2026, 7:27 PM EDT
Completed Phase 3 Interventional

Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome

NCT05701774
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
DCCR
Drug
Lead sponsor
Soleno Therapeutics, Inc.
Industry
Eligibility
4 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
17
States / cities
Orange, California • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 7:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Choline and Cardiometabolic Health

NCT04764162
View directory record Official record
Conditions
Cardiovascular Risk Factor
Interventions
Choline, Placebo
Dietary Supplement
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
18 Years to 79 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Blacksburg, Virginia
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 17, 2026, 7:27 PM EDT
Active, not recruiting Phase 2 Interventional

Choline Supplementation as a Neurodevelopmental Intervention in Fetal Alcohol Spectrum Disorders Study

NCT05108974
View directory record Official record
Conditions
Fetal Alcohol Spectrum Disorders
Interventions
Choline Bitartrate
Drug
Lead sponsor
Jeff Wozniak
Other
Eligibility
30 Months to 72 Months
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 17, 2026, 7:27 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood

NCT00639158
View directory record Official record
Conditions
Dyslipidemias, Coronary Heart Disease, Combined (Atherogenic) Dyslipidemia, Mixed Dyslipidemia
Interventions
ABT-335, placebo, atorvastatin, ezetimibe
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
543 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
118
States / cities
Birmingham, Alabama • Columbiana, Alabama • Hueytown, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2011 · Synced Oct 17, 2026, 7:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Supplemental Choline and Brain Development in Humans

NCT00678925
View directory record Official record
Conditions
Healthy
Interventions
Phosphatidylcholine, Corn oil placebo
Dietary Supplement
Lead sponsor
The Gerber Foundation
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 22, 2010 · Synced Oct 17, 2026, 7:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Fade Upon TOF Stimulation Induced by Succinylcholine

NCT02425449
View directory record Official record
Conditions
Muscle Relaxants
Interventions
Succinylcholine
Drug
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
18 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Oct 17, 2026, 7:27 PM EDT
Completed Early Phase 1 Interventional

PSMA and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate Cancer

NCT03768349
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ga-68 PSMA11, F-18 PSMA 1007
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 17, 2026, 7:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Carbon-11 Labeled Sarcosine in Prostate Cancer

NCT02462447
View directory record Official record
Conditions
Prostate Cancer
Interventions
11C-sarcosine, 11C-choline
Drug
Lead sponsor
University of Michigan
Other
Eligibility
40 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 17, 2026, 7:27 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effectiveness of Brief Intervention in Primary Care for Diverse Young People (Chat)

NCT06699251
View directory record Official record
Conditions
Adolescent Drinking, Cannabis Use
Interventions
Chat, Enhanced Usual Care
Behavioral
Lead sponsor
RAND
Other
Eligibility
12 Years to 19 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
3
States / cities
Commerce, California • North Hollywood, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 17, 2026, 7:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessment of TMAO Formation With Egg Intake Versus Choline Supplement in a Healthy Population

NCT03142763
View directory record Official record
Conditions
Cardiovascular Risk Factor
Interventions
Eggs, Choline Supplement
Other · Dietary Supplement
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years to 30 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 17, 2026, 7:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Pilot Study of Citicoline add-on Therapy in Patients With Bipolar Disorder or Major Depressive Disorder and Amphetamine Abuse or Dependence

NCT00377299
View directory record Official record
Conditions
Amphetamine Abuse, Amphetamine Dependence, Bipolar Disorder, Major Depressive Disorder
Interventions
Citicoline, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2013 · Synced Oct 17, 2026, 7:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Combination Effect of Citicoline and Omega-3

NCT03444662
View directory record Official record
Conditions
Healthy
Interventions
Placebo supplement, Citicoline and Omega-3 supplement, Omega-3 supplement
Dietary Supplement
Lead sponsor
Kyowa Hakko Bio Co., Ltd.
Industry
Eligibility
55 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 17, 2026, 7:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Trial to Investigate the Metabolism and Pharmacokinetics as Well as Safety and Tolerability of a Single Dose BI671800 HEA Administered as an Oral Solution of the Choline Salt in Healthy Male Volunteers

NCT01205373
View directory record Official record
Conditions
Healthy
Interventions
BI 671800
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 17, 2026, 7:27 PM EDT
Completed Phase 2 Interventional Results available

Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia

NCT02144675
View directory record Official record
Conditions
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
choline magnesium trisalicylate, idarubicin, cytarabine, laboratory biomarker analysis
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 17, 2026, 7:27 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)

NCT02016430
View directory record Official record
Conditions
Dietary Modification, Cardiovascular Risk Factor
Interventions
MeLT Dietary intervention, TLC Dietary intervention, MeLT dietary intervention with TMAO
Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 17, 2026, 7:27 PM EDT